Entrada Therapeutics Inc (TRDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $199.28M
Last updated: Nov 17, 2026 at 11:05 AM ET
Entrada Therapeutics Inc (TRDA) Competitors
The companies most similar to Entrada Therapeutics are Arcturus Therapeutics Holdings (ARCT), Rocket Pharmaceuticals (RCKT) and Invivyd (IVVD). By market cap, Entrada Therapeutics ranks 9th of the 13 companies on this page; Enanta Pharmaceuticals (ENTA) is the largest at $320.09M.
Peer Comparison
TRDA's ROIC of -69.7% is below the peer median of -6.7%, and its revenue growth of -43.9% is below the median of 3.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Entrada Therapeutics (TRDA) | $199.28M | N/A | 53.3x | 0.0% | -69.7% | -43.9% | 0.00% |
| Arcturus Therapeutics Holdings Inc (ARCT) | $240.96M | N/A | 7.7x | -285.9% | N/A | 6.7% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Protara Therapeutics Inc (TARA) | $155.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Enanta Pharmaceuticals Inc (ENTA) | $320.09M | N/A | 4.8x | -96.9% | N/A | -21.6% | 0.00% |
| ProQR Therapeutics BV (PRQR) | $199.28M | N/A | 6.1x | -228.2% | N/A | 120.4% | 0.00% |
| Bicycle Therapeutics Ltd (BCYC) | $236.22M | N/A | 2.7x | -169.8% | N/A | 190.2% | 0.00% |
| Q32 Bio Inc (QTTB) | $260.64M | 2.5x | 5.2x | 60.0% | N/A | 0.0% | 0.00% |
| Fate Therapeutics Inc (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| LENZ Therapeutics Inc (LENZ) | $129.77M | N/A | 9.7x | 0.0% | N/A | -72.9% | 0.00% |
| Lineage Cell Therapeutics Inc (LCTX) | $231.35M | N/A | 18.7x | 16.2% | -6.7% | -61.0% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| Peer median | $233.78M | 2.5x | 6.9x | -48.5% | -6.7% | 3.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Entrada Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Arcturus Therapeutics Holdings Inc (ARCT) | Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. | ARCT competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Protara Therapeutics Inc (TARA) | Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment... | TARA competitors |
| Enanta Pharmaceuticals Inc (ENTA) | Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. | ENTA competitors |
| ProQR Therapeutics BV (PRQR) | ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. | PRQR competitors |
| Bicycle Therapeutics Ltd (BCYC) | Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. | BCYC competitors |
| Q32 Bio Inc (QTTB) | Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune... | QTTB competitors |
| Fate Therapeutics Inc (FATE) | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. | FATE competitors |
| LENZ Therapeutics Inc (LENZ) | LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders... | LENZ competitors |
| Lineage Cell Therapeutics Inc (LCTX) | Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment... | LCTX competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
Frequently Asked Questions About TRDA
Who are Entrada Therapeutics' main competitors?
The companies most similar to Entrada Therapeutics include Arcturus Therapeutics Holdings (ARCT), Rocket Pharmaceuticals (RCKT), Invivyd (IVVD), Protara Therapeutics (TARA) and Enanta Pharmaceuticals (ENTA), listed from the closest match.
Who is Entrada Therapeutics' biggest competitor?
Enanta Pharmaceuticals (ENTA) is the largest of the similar companies at $320.09M; Arcturus Therapeutics Holdings (ARCT) is the closest match by business profile, size, sector and industry.
How does TRDA stock compare with its competitors?
TRDA's P/S is 53.3x against a peer median of 6.9x; its net margin is 0.0% against a peer median of -48.5%.
Which of Entrada Therapeutics' competitors pays a higher dividend?
Entrada Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Entrada Therapeutics bigger than its competitors?
No. Entrada Therapeutics is 9th by market cap among the 13 companies on this page; the largest is Enanta Pharmaceuticals (ENTA) at $320.09M.
TRDA pages: Overview, Earnings, Forecast, Financials, Competitors